Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Quarterly Earnings Results

Vanda Pharmaceuticals (NASDAQ:VNDA) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06, Zacks reports. Vanda Pharmaceuticals had a negative return on equity of 3.02% and a negative net margin of 8.59%. Vanda Pharmaceuticals updated its FY 2030 guidance to EPS and its FY 2025 guidance to EPS.

Vanda Pharmaceuticals Stock Down 1.1 %

Shares of NASDAQ VNDA traded down $0.05 during trading hours on Thursday, hitting $4.70. 937,216 shares of the stock were exchanged, compared to its average volume of 582,002. The firm has a fifty day moving average price of $4.63 and a 200-day moving average price of $4.87. The company has a market cap of $274.06 million, a PE ratio of -16.79 and a beta of 0.74. Vanda Pharmaceuticals has a 12 month low of $3.71 and a 12 month high of $6.75.

Wall Street Analysts Forecast Growth

VNDA has been the topic of several research reports. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, February 4th. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a “hold” rating for the company.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.